GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease
Highlights • GATA3 mutations were identified among 14% of ER-positive breast cancer patients • GATA3 mutations did not predict the response to tamoxifen for advanced disease • GATA3 mutations associate with an increased expression of GATA3 mRNA • GATA3 mRNA level is an independent predictor of longe...
Gespeichert in:
| Veröffentlicht in: | Cancer letters 2016-06, Vol.376 (1), p.104-109 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 109 |
|---|---|
| container_issue | 1 |
| container_start_page | 104 |
| container_title | Cancer letters |
| container_volume | 376 |
| creator | Liu, Jingjing Prager – van der Smissen, Wendy J.C Look, Maxime P Sieuwerts, Anieta M Smid, Marcel Meijer – van Gelder, Marion E Foekens, John A Hollestelle, Antoinette Martens, John W.M |
| description | Highlights • GATA3 mutations were identified among 14% of ER-positive breast cancer patients • GATA3 mutations did not predict the response to tamoxifen for advanced disease • GATA3 mutations associate with an increased expression of GATA3 mRNA • GATA3 mRNA level is an independent predictor of longer PFS during tamoxifen therapy • Other mechanisms, besides GATA3 mutations, exist that underlie high GATA3 levels |
| doi_str_mv | 10.1016/j.canlet.2016.03.038 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1805498439</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0304383516301987</els_id><sourcerecordid>1805498439</sourcerecordid><originalsourceid>FETCH-LOGICAL-c524t-b2c80c56fc2165d6b8827adbaf47016043ce493a66f33bcc2549112360723f6f3</originalsourceid><addsrcrecordid>eNqFkt1u1DAQhSMEoqXwBghZ4qYXZPFfHOcGaVWVglSBVMq15TiT4iWJF9tZ2ifj9ZiwC0i9qWTJ8ug7J5mZUxQvGV0xytTbzcrZaYC84vhaUYFHPyqOma55WTeaPi6OqaCyFFpUR8WzlDaU0krW1dPiiNeUaUHr4-LXxfp6Lch49WlN4HYbISUfpjeknTOZQibjnG3-U7EpBedthkR--vyNDGG6gUi2MdwcVGUfAUia487v7ED8RM6vym1IPvsdkDaCTZngT7tFhq4w5UQyljN0e8_ex5TLwU9Ash3Dre9hIn2IJIKbY0QB6XxCH3hePOntkODF4T4pvr4_vz77UF5-vvh4tr4sXcVlLlvuNHWV6h1nqupUqzWvbdfaXuIIFJXCgWyEVaoXonWOV7JhjAtFay56LJ4Up3tf7PPHDCmb0ScHw2AnCHMyTONMGy1F8zBa66qWqpIc0df30E2Y44SNLBQiSmmBlNxTLoaUIvRmG_1o451h1CwZMBuzz4BZMmCowKNR9upgPrcjdP9Ef5eOwLs9ADi4nYdoksNlOOg8zjmbLviHvnDfwOHOvLPDd7iD9L8Xk7ih5suSwyWGTAnKGl2L32E_24M</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1786546683</pqid></control><display><type>article</type><title>GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Liu, Jingjing ; Prager – van der Smissen, Wendy J.C ; Look, Maxime P ; Sieuwerts, Anieta M ; Smid, Marcel ; Meijer – van Gelder, Marion E ; Foekens, John A ; Hollestelle, Antoinette ; Martens, John W.M</creator><creatorcontrib>Liu, Jingjing ; Prager – van der Smissen, Wendy J.C ; Look, Maxime P ; Sieuwerts, Anieta M ; Smid, Marcel ; Meijer – van Gelder, Marion E ; Foekens, John A ; Hollestelle, Antoinette ; Martens, John W.M</creatorcontrib><description>Highlights • GATA3 mutations were identified among 14% of ER-positive breast cancer patients • GATA3 mutations did not predict the response to tamoxifen for advanced disease • GATA3 mutations associate with an increased expression of GATA3 mRNA • GATA3 mRNA level is an independent predictor of longer PFS during tamoxifen therapy • Other mechanisms, besides GATA3 mutations, exist that underlie high GATA3 levels</description><identifier>ISSN: 0304-3835</identifier><identifier>EISSN: 1872-7980</identifier><identifier>DOI: 10.1016/j.canlet.2016.03.038</identifier><identifier>PMID: 27018307</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>Antineoplastic Agents, Hormonal - adverse effects ; Antineoplastic Agents, Hormonal - therapeutic use ; Biomarkers, Tumor - genetics ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - genetics ; Breast Neoplasms - metabolism ; Breast Neoplasms - mortality ; Cancer therapies ; Chemotherapy ; Chi-Square Distribution ; Disease-Free Survival ; DNA Mutational Analysis ; Expression ; Female ; GATA3 ; GATA3 Transcription Factor - genetics ; Gene expression ; Gene Expression Regulation, Neoplastic ; Hematology, Oncology and Palliative Medicine ; Humans ; Kaplan-Meier Estimate ; Logistic Models ; Medical prognosis ; Multivariate Analysis ; Mutation ; Neoplasm Recurrence, Local ; Odds Ratio ; Proportional Hazards Models ; Protein expression ; Proteins ; Receptors, Estrogen - antagonists & inhibitors ; Receptors, Estrogen - metabolism ; Recurrent breast cancer ; Retrospective Studies ; Risk Factors ; RNA, Messenger - genetics ; Rodents ; Selective Estrogen Receptor Modulators - adverse effects ; Selective Estrogen Receptor Modulators - therapeutic use ; Tamoxifen ; Tamoxifen - adverse effects ; Tamoxifen - therapeutic use ; Time Factors ; Treatment Outcome</subject><ispartof>Cancer letters, 2016-06, Vol.376 (1), p.104-109</ispartof><rights>2016 The Authors</rights><rights>Copyright © 2016 The Authors. Published by Elsevier Ireland Ltd.. All rights reserved.</rights><rights>Copyright Elsevier Limited Jun 28, 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c524t-b2c80c56fc2165d6b8827adbaf47016043ce493a66f33bcc2549112360723f6f3</citedby><cites>FETCH-LOGICAL-c524t-b2c80c56fc2165d6b8827adbaf47016043ce493a66f33bcc2549112360723f6f3</cites><orcidid>0000-0003-1166-1966 ; 0000-0002-3428-3366</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0304383516301987$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27018307$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, Jingjing</creatorcontrib><creatorcontrib>Prager – van der Smissen, Wendy J.C</creatorcontrib><creatorcontrib>Look, Maxime P</creatorcontrib><creatorcontrib>Sieuwerts, Anieta M</creatorcontrib><creatorcontrib>Smid, Marcel</creatorcontrib><creatorcontrib>Meijer – van Gelder, Marion E</creatorcontrib><creatorcontrib>Foekens, John A</creatorcontrib><creatorcontrib>Hollestelle, Antoinette</creatorcontrib><creatorcontrib>Martens, John W.M</creatorcontrib><title>GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease</title><title>Cancer letters</title><addtitle>Cancer Lett</addtitle><description>Highlights • GATA3 mutations were identified among 14% of ER-positive breast cancer patients • GATA3 mutations did not predict the response to tamoxifen for advanced disease • GATA3 mutations associate with an increased expression of GATA3 mRNA • GATA3 mRNA level is an independent predictor of longer PFS during tamoxifen therapy • Other mechanisms, besides GATA3 mutations, exist that underlie high GATA3 levels</description><subject>Antineoplastic Agents, Hormonal - adverse effects</subject><subject>Antineoplastic Agents, Hormonal - therapeutic use</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - mortality</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Chi-Square Distribution</subject><subject>Disease-Free Survival</subject><subject>DNA Mutational Analysis</subject><subject>Expression</subject><subject>Female</subject><subject>GATA3</subject><subject>GATA3 Transcription Factor - genetics</subject><subject>Gene expression</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Logistic Models</subject><subject>Medical prognosis</subject><subject>Multivariate Analysis</subject><subject>Mutation</subject><subject>Neoplasm Recurrence, Local</subject><subject>Odds Ratio</subject><subject>Proportional Hazards Models</subject><subject>Protein expression</subject><subject>Proteins</subject><subject>Receptors, Estrogen - antagonists & inhibitors</subject><subject>Receptors, Estrogen - metabolism</subject><subject>Recurrent breast cancer</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>RNA, Messenger - genetics</subject><subject>Rodents</subject><subject>Selective Estrogen Receptor Modulators - adverse effects</subject><subject>Selective Estrogen Receptor Modulators - therapeutic use</subject><subject>Tamoxifen</subject><subject>Tamoxifen - adverse effects</subject><subject>Tamoxifen - therapeutic use</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>0304-3835</issn><issn>1872-7980</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkt1u1DAQhSMEoqXwBghZ4qYXZPFfHOcGaVWVglSBVMq15TiT4iWJF9tZ2ifj9ZiwC0i9qWTJ8ug7J5mZUxQvGV0xytTbzcrZaYC84vhaUYFHPyqOma55WTeaPi6OqaCyFFpUR8WzlDaU0krW1dPiiNeUaUHr4-LXxfp6Lch49WlN4HYbISUfpjeknTOZQibjnG3-U7EpBedthkR--vyNDGG6gUi2MdwcVGUfAUia487v7ED8RM6vym1IPvsdkDaCTZngT7tFhq4w5UQyljN0e8_ex5TLwU9Ash3Dre9hIn2IJIKbY0QB6XxCH3hePOntkODF4T4pvr4_vz77UF5-vvh4tr4sXcVlLlvuNHWV6h1nqupUqzWvbdfaXuIIFJXCgWyEVaoXonWOV7JhjAtFay56LJ4Up3tf7PPHDCmb0ScHw2AnCHMyTONMGy1F8zBa66qWqpIc0df30E2Y44SNLBQiSmmBlNxTLoaUIvRmG_1o451h1CwZMBuzz4BZMmCowKNR9upgPrcjdP9Ef5eOwLs9ADi4nYdoksNlOOg8zjmbLviHvnDfwOHOvLPDd7iD9L8Xk7ih5suSwyWGTAnKGl2L32E_24M</recordid><startdate>20160628</startdate><enddate>20160628</enddate><creator>Liu, Jingjing</creator><creator>Prager – van der Smissen, Wendy J.C</creator><creator>Look, Maxime P</creator><creator>Sieuwerts, Anieta M</creator><creator>Smid, Marcel</creator><creator>Meijer – van Gelder, Marion E</creator><creator>Foekens, John A</creator><creator>Hollestelle, Antoinette</creator><creator>Martens, John W.M</creator><general>Elsevier Ireland Ltd</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>7U7</scope><scope>C1K</scope><orcidid>https://orcid.org/0000-0003-1166-1966</orcidid><orcidid>https://orcid.org/0000-0002-3428-3366</orcidid></search><sort><creationdate>20160628</creationdate><title>GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease</title><author>Liu, Jingjing ; Prager – van der Smissen, Wendy J.C ; Look, Maxime P ; Sieuwerts, Anieta M ; Smid, Marcel ; Meijer – van Gelder, Marion E ; Foekens, John A ; Hollestelle, Antoinette ; Martens, John W.M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c524t-b2c80c56fc2165d6b8827adbaf47016043ce493a66f33bcc2549112360723f6f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Antineoplastic Agents, Hormonal - adverse effects</topic><topic>Antineoplastic Agents, Hormonal - therapeutic use</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - mortality</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Chi-Square Distribution</topic><topic>Disease-Free Survival</topic><topic>DNA Mutational Analysis</topic><topic>Expression</topic><topic>Female</topic><topic>GATA3</topic><topic>GATA3 Transcription Factor - genetics</topic><topic>Gene expression</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Logistic Models</topic><topic>Medical prognosis</topic><topic>Multivariate Analysis</topic><topic>Mutation</topic><topic>Neoplasm Recurrence, Local</topic><topic>Odds Ratio</topic><topic>Proportional Hazards Models</topic><topic>Protein expression</topic><topic>Proteins</topic><topic>Receptors, Estrogen - antagonists & inhibitors</topic><topic>Receptors, Estrogen - metabolism</topic><topic>Recurrent breast cancer</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>RNA, Messenger - genetics</topic><topic>Rodents</topic><topic>Selective Estrogen Receptor Modulators - adverse effects</topic><topic>Selective Estrogen Receptor Modulators - therapeutic use</topic><topic>Tamoxifen</topic><topic>Tamoxifen - adverse effects</topic><topic>Tamoxifen - therapeutic use</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, Jingjing</creatorcontrib><creatorcontrib>Prager – van der Smissen, Wendy J.C</creatorcontrib><creatorcontrib>Look, Maxime P</creatorcontrib><creatorcontrib>Sieuwerts, Anieta M</creatorcontrib><creatorcontrib>Smid, Marcel</creatorcontrib><creatorcontrib>Meijer – van Gelder, Marion E</creatorcontrib><creatorcontrib>Foekens, John A</creatorcontrib><creatorcontrib>Hollestelle, Antoinette</creatorcontrib><creatorcontrib>Martens, John W.M</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Cancer letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Jingjing</au><au>Prager – van der Smissen, Wendy J.C</au><au>Look, Maxime P</au><au>Sieuwerts, Anieta M</au><au>Smid, Marcel</au><au>Meijer – van Gelder, Marion E</au><au>Foekens, John A</au><au>Hollestelle, Antoinette</au><au>Martens, John W.M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease</atitle><jtitle>Cancer letters</jtitle><addtitle>Cancer Lett</addtitle><date>2016-06-28</date><risdate>2016</risdate><volume>376</volume><issue>1</issue><spage>104</spage><epage>109</epage><pages>104-109</pages><issn>0304-3835</issn><eissn>1872-7980</eissn><abstract>Highlights • GATA3 mutations were identified among 14% of ER-positive breast cancer patients • GATA3 mutations did not predict the response to tamoxifen for advanced disease • GATA3 mutations associate with an increased expression of GATA3 mRNA • GATA3 mRNA level is an independent predictor of longer PFS during tamoxifen therapy • Other mechanisms, besides GATA3 mutations, exist that underlie high GATA3 levels</abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>27018307</pmid><doi>10.1016/j.canlet.2016.03.038</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-1166-1966</orcidid><orcidid>https://orcid.org/0000-0002-3428-3366</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0304-3835 |
| ispartof | Cancer letters, 2016-06, Vol.376 (1), p.104-109 |
| issn | 0304-3835 1872-7980 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1805498439 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Antineoplastic Agents, Hormonal - adverse effects Antineoplastic Agents, Hormonal - therapeutic use Biomarkers, Tumor - genetics Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - metabolism Breast Neoplasms - mortality Cancer therapies Chemotherapy Chi-Square Distribution Disease-Free Survival DNA Mutational Analysis Expression Female GATA3 GATA3 Transcription Factor - genetics Gene expression Gene Expression Regulation, Neoplastic Hematology, Oncology and Palliative Medicine Humans Kaplan-Meier Estimate Logistic Models Medical prognosis Multivariate Analysis Mutation Neoplasm Recurrence, Local Odds Ratio Proportional Hazards Models Protein expression Proteins Receptors, Estrogen - antagonists & inhibitors Receptors, Estrogen - metabolism Recurrent breast cancer Retrospective Studies Risk Factors RNA, Messenger - genetics Rodents Selective Estrogen Receptor Modulators - adverse effects Selective Estrogen Receptor Modulators - therapeutic use Tamoxifen Tamoxifen - adverse effects Tamoxifen - therapeutic use Time Factors Treatment Outcome |
| title | GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T15%3A22%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=GATA3%20mRNA%20expression,%20but%20not%20mutation,%20associates%20with%20longer%20progression-free%20survival%20in%20ER-positive%20breast%20cancer%20patients%20treated%20with%20first-line%20tamoxifen%20for%20recurrent%20disease&rft.jtitle=Cancer%20letters&rft.au=Liu,%20Jingjing&rft.date=2016-06-28&rft.volume=376&rft.issue=1&rft.spage=104&rft.epage=109&rft.pages=104-109&rft.issn=0304-3835&rft.eissn=1872-7980&rft_id=info:doi/10.1016/j.canlet.2016.03.038&rft_dat=%3Cproquest_cross%3E1805498439%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1786546683&rft_id=info:pmid/27018307&rft_els_id=1_s2_0_S0304383516301987&rfr_iscdi=true |